The Microchemistry and Proteomics (MCP) Core provides mass spectrometric sequencing and quantitation of peptides and proteins to support basic, translational, and clinical research programs at MSK. The Core utilizes modern high-resolution mass spectrometry and nanoscale liquid chromatography in conjuction with biochemical processing of samples with the end goal of determining the identity, relative abundance, and presence of post translational modifications from purified components, cell lysates, tissues, and select fluid such as cerebral spinal fluid. Proteins and post translational modification are critical components of complex signaling pathways underlying development, cell growth, differentiation, DNA repair, senescence, immune response to cancer, and response to bioactive therapies. Dissection of these pathways can lead to insights on the underlying molecular mechanisms involved in cancer. The goal of the MCP Core is to be an efficient, user friendly, state-of-the-art facility. Advice is provided by the Core staff to facilitate the design, execution, and analysis of experiments. Over the past year, the Core has supported research from 38 investigators. Over the past grant period, investigators from all 10 programs have been supported, and the Core has contributed to 207 publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-53
Application #
9631244
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
53
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Salo-Mullen, Erin E; Lynn, Patricio B; Wang, Lu et al. (2018) Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. Fam Cancer 17:71-77
Sigel, Carlie S; Krauss Silva, Vitor Werneck; Reid, Michelle D et al. (2018) Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study. Cancer Cytopathol 126:44-53
Sauter, Craig S; Matasar, Matthew J; Schoder, Heiko et al. (2018) A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood 131:1805-1808
Berry, Sean L; Tierney, Kevin P; Elguindi, Sharif et al. (2018) Five years' experience with a customized electronic checklist for radiation therapy planning quality assurance in a multicampus institution. Pract Radiat Oncol 8:279-286
Breitbart, William (2018) Jimmie C. Holland, M.D. Psychosomatics 59:123-124
Geller, Shamir; Pitter, Ken; Moskowitz, Alison et al. (2018) Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy. Clin Lymphoma Myeloma Leuk 18:e279-e281
Romesser, Paul B; Pei, Xin; Shi, Weiji et al. (2018) Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. Int J Radiat Oncol Biol Phys 100:59-67
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Scott, Jessica M; Nilsen, Tormod S; Gupta, Dipti et al. (2018) Exercise Therapy and Cardiovascular Toxicity in Cancer. Circulation 137:1176-1191
Routy, Bertrand; Le Chatelier, Emmanuelle; Derosa, Lisa et al. (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91-97

Showing the most recent 10 out of 8799 publications